A Phase II Trial of PTK-787 [vatalanib] in Recurrent or Progressive Meningiomas.

Trial Profile

A Phase II Trial of PTK-787 [vatalanib] in Recurrent or Progressive Meningiomas.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Vatalanib (Primary)
  • Indications Meningioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2014 Status changed from active, no longer recruiting to completedas as reported by ClinicalTrials.gov.
    • 21 Mar 2013 Planned End Date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.
    • 22 Oct 2012 Planned end date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top